



21

YEARS IN OPERATION

Established in 2003, initially as a Public Private Partnership between the Biovac Consortium and the South African Government.



350

EMPLOYEES

Of whom 53% is female, 3% is living with disabilities, 94% is black, 40% have an undergraduate or postgraduate degree and 20% have a diploma.



15.5

BILLION RAND CONTRIBUTED

Directly and indirectly to South Africa's GDP due to localising the production of key vaccines in our current manufacturing pipeline.



33

MILLION VACCINE DOSES

Average amount of vaccine doses delivered to Department of Health clinics and depots across all provinces in South Africa and export distribution to the African continent.



OUR PROUDEST INNOVATIONS:

Through our bacterial based fermentation, conjugation and purification platforms, we are proud of our world class vaccine development capabilities as demonstrated through our involvement in the development of Haemophilus Influenzae b, Group B Streptococcus and Cholera.

WHAT WE DELIVER TO THE PUBLIC:

- We are a proudly South African, locally black owned company and a level 1 BBBEE contributor.
- We've created 8500 job opportunities directly as well as indirectly through our value chain and partnerships, with further job creation envisaged through our Africa growth strategy.
- We deliver preventative medicines that form the cornerstone of primary health care.
- We contribute to the innovation chasm & the knowledge economy within biotech.
- Over R1bn foreign investment has flown into South Africa through our successful partnerships with Sanofi & Pfizer. These partnerships have enabled local infrastructure building, the transfer of sophisticated technology and the building of scarce aseptic manufacturing skills. Importantly, these partnerships have resulted in improved security of local supply, reduced import costs of finished products and contribute towards the sustainability of our local vaccine manufacturing industry.
- Producing vaccines locally significantly contributes to South Africa's GDP with a total direct and indirect impact of R15.5 billion.
- Biovac showcases South Africa, and indeed Africa, as a biotechnology investment destination, and that's why we are.

LOOKING AHEAD:

- Raise capital for facility expansion and products due to pipeline growth.
- Build and commercialise new facility for growing product pipeline.
- Obtain WHO prequalification.
- Expand our footprint further into the rest of Africa and global markets.
- Continuously build our brand as an employer of choice.
- New facility building in advanced stage and equipment in validation phase.
- Deliver against defence strategy for current pipeline.
- Digitally transform our business.



CONTACT US

15 Alexandra Road, Pinelands, 7405
Cape Town, South Africa
+27 21 514 5000
www.biovac.co.za



Sales & Marketing: salesmarketing@biovac.co.za
Pharmacovigilance: drugsafety@biovac.co.za
Recruitment: recruitment@biovac.co.za
Media & PR: media@biovac.co.za
General: general@biovac.co.za

BBBEE LEVEL